

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated:

3-22-05

Signature:

Maura A. Gallagher

(Maura A. Gallagher)

3-16-15  
Docket No.: ASZD-P01-663  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Whittamore et al.

Application No.: 10/506554

Confirmation No.: 1655

Filed: September 1, 2004

Art Unit: 1615

For: INDOLAMID DERIVATIVES WHICH  
POSSESS GLYCOGENPHOSPHORYLASE  
INHIBITORY ACTIVITY

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A summary/abstract translation of the non-English language references is enclosed.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this


Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-663. A duplicate copy of this paper is enclosed.

Dated: March 22, 2005

Respectfully submitted,

By 

David P. Halstead

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/506554
				Filing Date	September 1, 2004
				First Named Inventor	Paul Robert Owen Whittamore
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-663

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-2004/0002495-A1	01-01-2004	Philip Sher	
	AB	US-3,706,810	12-19-1972	AMERICAN CYANAMID	
	AC	US-4,599,198	07-08-1986	DENNIS J. HOOVER	
	AD	US-4,668,769	05-26-1987	DENNIS J. HOOVER	
	AE	US-4,720,503	01-19-1988	BRUCE E. WITZEL	
	AF	US-4,751,231	06-14-1988	WASYL HALCZENKO	
	AG	US-4,786,641	11-22-1988	SIEGFRIED GOLDMANN	
	AH	US-4,794,120	12-27-1988	PHILIPPE MANOURY	
	AI	US-5,863,903	01-26-1999	KARSTEN LUNDGREN	
	AJ	US-5,998,463	12-07-1999	BERNARD HULIN	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-00/42213	07-20-2000	The Research Foundation of State University of New York		
	BB	WO-00/47206	08-17-2000	Novo Nordisk		
	BC	WO-01/05954	01-25-2001	Isis Pharmaceuticals, Inc.		
	BD	WO-01/23347	04-05-2001	Novo Nordisk		
	BE	WO-01/32654	05-10-2001	Societe de Conseils de Recherches et D'Applications Scientifiques		
	BF	WO-01/52825	07-26-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.		
	BG	WO-01/68055	09-20-2001	Pfizer Products Inc.		
	BH	WO-01/68092	09-20-2001	Pfizer Products Inc.		
	BI	WO-01/68603	09-20-2001	Bristol-Myers Squibb Co.		
	BJ	WO-01/94300	12-13-2001	Aventis Pharma Deutschland		
	BK	WO-01/96311	12-20-2001	Bristol-Myers Squibb Company		
	BL	WO-01/96347	12-20-2001	Bristol-Myers Squibb Company		
	BM	WO-02/080844	10-17-2002	Genzyme Corporation		
	BN	WO-02/096864	12-05-2002	Aventis Pharma Deutschland GmbH		
	BO	WO-02/098348	12-12-2002	Eli Lilly and Company		
	BP	WO-02/26714	04-04-2002	Takeda Chemical Industries, Ltd.		
	BQ	WO-02/34718	05-02-2002	Richter Gedeon Vegyeszeti Gyar Rt.		
	BR	WO-03/037864	05-08-2003	Japan Tobacco Inc.		
	BS	EP-0846464	06-10-1998	Pfizer Inc.		
	BT	EP-0884050	12-16-1998	Novo Nordisk		
	BU	EP-0978279	02-09-2000	Pfizer Products Inc.		
	BV	EP-1088824	01-07-2004	Pfizer Products Inc.		
	BW	EP-1125580	08-22-2001	Pfizer Products Inc.		
	BX	EP-1134213	09-19-2001	Pfizer Inc.		
	BY	EP-1136071	09-26-2001	Pfizer Products Inc.		
Examiner Signature				Date Considered		



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/506554		
		Filing Date	September 1, 2004		
		First Named Inventor	Paul Robert Owen Whittamore		
		Art Unit	1615		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-663

	BZ	EP-1145717	05-12-2004	Pfizer Products Inc.		
	BA1	EP-1149580	02-21-2001	Pfizer Products Inc.		
	BB1	EP-1177791	07-27-2001	Pfizer Products Inc.		
	BC1	ES-2081747	03-01-1996	Esteve Labor DR		
	BD1	DE-4445968	06-27-1996	Bayer AG		
	BE1	WO-93/25574	12-23-1993	Pfizer Inc.		
	BF1	WO-95/24391	09-14-1995	Novo Nordisk		
	BG1	WO-96/39384	12-12-1996	Pfizer, Inc.		
	BH1	WO-96/39385	12-12-1996	Pfizer Inc.		
	BI1	WO-97/09040	03-13-1997	Novo Nordisk		
	BJ1	WO-97/31901	09-04-1997	Mikael Bols		
	BK1	WO-97/45425	12-04-1997	Fujisawa Pharmaceutical Co., Ltd.		
	BL1	WO-98/27108	06-25-1998	Fuji-Sawa Pharmaceutical Co., Ltd.		
	BM1	WO-98/40353	09-17-1998	Novo Nordisk		
	BN1	WO-98/50359	11-12-1998	Novo Nordisk		
	BO1	WO-99/26659	06-03-1999	Pfizer Products Inc.		
	BP1	WO-99/36393	07-22-1999	Tanabe Seiyaku Co., Ltd.		
	BQ1	JP 2001 089368				
	BR1	DD 200740	06-08-1983	Gewald		
	BS1	EP 697403	02-21-1996	Sanofi		
	BT1	JP 2001 206856	07-31-2001	Pfizer Prod. Inc.		
	BU1	JP 021247565	05-14-1990	Hanawa Netsuden Kinzoku KK		
				Toray Ind. Inc.		
	BV1	JP 04179949	06-26-1992			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.		
	CB	Crochet, R.A., et al., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).		
	CC	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340.		
	CD	Hartman, G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 29(10):1943-1949 (1989).		
	CE	Hoover, D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 41:2934-2938 (1998).		
	CF	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002).		
	CG	Jakobsen, P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase,"		
Examiner Signature				Date Considered



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/506554
				Filing Date	September 1, 2004
				First Named Inventor	Paul Robert Owen Whittamore
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-663

		Bioorganic Med. Chem., 9:733-744 (2001).	
	CH	Martin, W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, 95:1776-1781 (Feb. 1998).	
	CI	McCormack, J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 7:1451-1474 (2001).	
	CJ	Oikonomakos, N.G., et al., "Allosteric inhibition of glycogen phosphorylase alpha by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methylpyridine-3,5,6-tricarboxylate," Protein Sci., 8:1930-1945 (1999).	
	CK	Rath, V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, 6:139-148 (July 2000).	
	CL	Rosauer, K.G., et al., "Novel, 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 13:4385-4388 (2003).	
	CM	Soman, G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase beta," Biochimica et Biophysica Acta, 358:359-362 (1974).	
	CN	Soman, G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase beta," Biochem. J., 147:369-371 (1975).	
	CO	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 1, A365, 1521-P	
	CP	Treadway, J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 10(3):439-454 (2001).	
	CQ	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343.	
	CR	Venkatarangan, P., et al., "Prediction of Ligand-REceptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 42:2169-2179 (1999).	
	CS	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetes, 47, Supp., 589, A214.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--